Literature DB >> 17580260

Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses.

Seitaro Terakura1, Eiichi Azuma, Makoto Murata, Tadashi Kumamoto, Masahiro Hirayama, Yoshiko Atsuta, Yoshihisa Kodera, Makoto Yazaki, Tomoki Naoe, Koji Kato.   

Abstract

Umbilical cord blood (UCB) transplantation is limited by the low number of hematopoietic stem cells in UCB units, which results in a low engraftment rate in transplant recipients. Here, we measured the total nucleated cell count and CD34(+), CD3(+), CD4(+), CD8(+), CD14(+), and CD16(+)/56(+) cell doses in each UCB unit and evaluated their influence on engraftment and other outcomes in 146 recipients. Multivariate analysis showed a significant association between a higher incidence of successful engraftment and a dose of CD34(+) and CD8(+) cells above the median (1.4 x 10(5) and 15.7 x 10(5) cells/kg, respectively). Engraftment occurred 4 days earlier in patients who received UCB with more than the median dose of CD34(+) cells than those receiving UCB at or below the median. Stratification of the group according to CD34(+) cell dose revealed a significant influence of the CD8(+) cell dose on the time to achieve neutrophil engraftment in patients receiving a lower CD34(+) cell dose, whereas there was no significant influence in the patients receiving a higher CD34(+) cell dose. These results suggest that consideration of CD34(+) and CD8(+) cell doses in UCB units may improve the engraftment in recipients of UCB transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580260     DOI: 10.1016/j.bbmt.2007.03.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

1.  The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME).

Authors:  Kristin M Page; Lijun Zhang; Adam Mendizabal; Stephen Wease; Shelly Carter; Kevin Shoulars; Tracy Gentry; Andrew E Balber; Joanne Kurtzberg
Journal:  Transfusion       Date:  2011-08-02       Impact factor: 3.157

2.  Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning.

Authors:  M Koyama; D Hashimoto; K Nagafuji; T Eto; Y Ohno; K Aoyama; H Iwasaki; T Miyamoto; G R Hill; K Akashi; T Teshima
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

3.  A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin.

Authors:  Tetsuya Nishida; Takeshi Kobayashi; Masashi Sawa; Shinichi Masuda; Yasuhiko Shibasaki; Tatsunori Goto; Noriko Fukuhara; Nobuharu Fujii; Kazuhiro Ikegame; Junichi Sugita; Takashi Ikeda; Yachiyo Kuwatsuka; Ritsuro Suzuki; Yuho Najima; Noriko Doki; Tomonori Kato; Yuichiro Inagaki; Yoshikazu Utsu; Nobuyuki Aotsuka; Masayoshi Masuko; Seitaro Terakura; Yasushi Onishi; Yoshinobu Maeda; Masaya Okada; Takanori Teshima; Makoto Murata
Journal:  Ann Hematol       Date:  2021-01-11       Impact factor: 3.673

4.  Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.

Authors:  N Kawashima; S Terakura; S Nishiwaki; D Koyama; Y Ozawa; M Ito; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

5.  GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.

Authors:  S Terakura; Y Kuwatsuka; S Yamasaki; A Wake; J Kanda; Y Inamoto; S Mizuta; T Yamaguchi; N Uchida; Y Kouzai; N Aotsuka; H Ogawa; H Kanamori; K Nishiwaki; S Miyakoshi; M Onizuka; I Amano; T Fukuda; T Ichinohe; Y Atsuta; M Murata; T Teshima
Journal:  Bone Marrow Transplant       Date:  2017-06-12       Impact factor: 5.483

6.  Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.

Authors:  Seitaro Terakura; Yachiyo Kuwatsuka; Junichi Sugita; Satoshi Takahashi; Yukiyasu Ozawa; Kazutaka Ozeki; Satoshi Yoshioka; Hirohisa Nakamae; Toshiro Kawakita; Masashi Sawa; Satoshi Morishige; Yuho Najima; Yuna Katsuoka; Emiko Sakaida; Yasuji Kouzai; Takafumi Kimura; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Makoto Murata; Takanori Teshima
Journal:  Int J Hematol       Date:  2021-02-21       Impact factor: 2.490

Review 7.  Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.

Authors:  Haesook T Kim; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-07       Impact factor: 5.742

8.  Thrombopoietin treatment of one graft in a double cord blood transplant provides early platelet recovery while contributing to long-term engraftment in NSG mice.

Authors:  Mark van der Garde; Yvette van Hensbergen; Anneke Brand; Manon C Slot; Alice de Graaf-Dijkstra; Arend Mulder; Suzanne M Watt; Jaap Jan Zwaginga
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

9.  Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies.

Authors:  T L Kindwall-Keller; Y Hegerfeldt; H J Meyerson; S Margevicius; P Fu; W van Heeckeren; H M Lazarus; B W Cooper; S L Gerson; P Barr; W W Tse; C Curtis; L R Fanning; R J Creger; J M Carlson-Barko; M J Laughlin
Journal:  Bone Marrow Transplant       Date:  2011-10-17       Impact factor: 5.483

10.  Natural Killer Cells Improve Hematopoietic Stem Cell Engraftment by Increasing Stem Cell Clonogenicity In Vitro and in a Humanized Mouse Model.

Authors:  Michelle Escobedo-Cousin; Nicola Jackson; Raquel Laza-Briviesca; Linda Ariza-McNaughton; Martha Luevano; Sophie Derniame; Sergio Querol; Michael Blundell; Adrian Thrasher; Bernat Soria; Nichola Cooper; Dominique Bonnet; Alejandro Madrigal; Aurore Saudemont
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.